Anixa Biosciences (ANIX) Competitors $3.35 +0.16 (+5.02%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.28 -0.08 (-2.24%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. PGEN, RAPP, ORKA, PRTC, RGNX, TRML, ETON, ITOS, RZLT, and RVNCShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Precigen (PGEN), Rapport Therapeutics (RAPP), Oruka Therapeutics (ORKA), PureTech Health (PRTC), REGENXBIO (RGNX), Tourmaline Bio (TRML), Eton Pharmaceuticals (ETON), iTeos Therapeutics (ITOS), Rezolute (RZLT), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Its Competitors Precigen Rapport Therapeutics Oruka Therapeutics PureTech Health REGENXBIO Tourmaline Bio Eton Pharmaceuticals iTeos Therapeutics Rezolute Revance Therapeutics Anixa Biosciences (NASDAQ:ANIX) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends. Which has stronger earnings and valuation, ANIX or PGEN? Anixa Biosciences has higher earnings, but lower revenue than Precigen. Anixa Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa Biosciences$210K513.83-$12.55M-$0.38-8.82Precigen$3.92M122.36-$126.24M-$0.56-2.90 Do institutionals and insiders hold more shares of ANIX or PGEN? 29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 25.3% of Anixa Biosciences shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, ANIX or PGEN? Anixa Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Does the media prefer ANIX or PGEN? In the previous week, Precigen had 3 more articles in the media than Anixa Biosciences. MarketBeat recorded 3 mentions for Precigen and 0 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 0.00 equaled Precigen'saverage media sentiment score. Company Overall Sentiment Anixa Biosciences Neutral Precigen Neutral Is ANIX or PGEN more profitable? Anixa Biosciences has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Anixa Biosciences' return on equity of -68.17% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -68.17% -60.38% Precigen -3,728.87%-279.20%-79.74% Do analysts rate ANIX or PGEN? Anixa Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 168.66%. Precigen has a consensus price target of $6.00, suggesting a potential upside of 269.23%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Anixa Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAnixa Biosciences beats Precigen on 8 of the 15 factors compared between the two stocks. Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.04M$2.90B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-8.8221.5627.5820.25Price / Sales513.83281.07417.23118.60Price / CashN/A42.7336.8958.07Price / Book7.287.518.035.67Net Income-$12.55M-$55.05M$3.18B$249.21M7 Day Performance4.04%4.61%2.91%3.28%1 Month Performance17.96%4.72%3.72%5.56%1 Year Performance46.29%5.92%36.04%21.13% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences2.6738 of 5 stars$3.35+5.0%$9.00+168.7%+47.6%$104.04M$210K-8.825Positive NewsPGENPrecigen3.7179 of 5 stars$1.42flat$6.00+322.5%+10.5%$419.16M$3.92M-2.54190News CoverageRAPPRapport Therapeutics1.3457 of 5 stars$11.37-0.5%$32.67+187.3%-48.3%$415.01MN/A-3.30N/AGap UpORKAOruka Therapeutics2.2099 of 5 stars$11.21+1.2%$40.38+260.2%N/A$414.85MN/A-2.49N/ANews CoveragePRTCPureTech Health2.0409 of 5 stars$17.25+0.6%$45.00+160.9%-22.2%$414.35M$4.83M0.00100Gap UpRGNXREGENXBIO4.5337 of 5 stars$8.21-2.1%$31.63+285.2%-19.3%$411.81M$156.72M-2.64370Positive NewsTRMLTourmaline Bio2.1399 of 5 stars$15.99-3.3%$49.33+208.5%+30.7%$410.62MN/A-4.9844ETONEton Pharmaceuticals2.5145 of 5 stars$14.25+1.7%$29.67+108.2%+341.5%$382.19M$39.01M-79.1720ITOSiTeos Therapeutics3.2089 of 5 stars$9.97+0.2%$15.86+59.0%-31.2%$381.55M$35M-3.2890RZLTRezolute3.0793 of 5 stars$4.46+2.5%$11.83+165.3%+14.5%$381.42MN/A-3.8840Positive NewsHigh Trading VolumeRVNCRevance Therapeutics2.7741 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies Precigen Alternatives Rapport Therapeutics Alternatives Oruka Therapeutics Alternatives PureTech Health Alternatives REGENXBIO Alternatives Tourmaline Bio Alternatives Eton Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Rezolute Alternatives Revance Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
